Not so fast NOVAVAX, not so fast! 2 studies indicate risk of heart damage (myocarditis & pericarditis alike for Pfizer etc.) using NOVAVAX vaccine, it too has SERIOUS risks; NEVER studied safety risks

Researchers did not study safety for children or for pregnant women, never did biodistribution studies etc. Same failures as the Pfizer and Moderna COVID mRNA vaccine studies

https://link.springer.com/article/10.1007/s40801-023-00355-5?utm_source=substack&utm_medium=email

Alexander COVID News-Dr. Paul Elias Alexander’s Newsletter is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

‘In total, 61 ICSRs included NVX-CoV2373. Most of the reports originated in Australia (50; 82.0%); 24 (39.3%) were considered serious….
The median age of individuals was 35.5 years old, and most were males (38; 62.3%). Chest pain was the most common co-reported event 43 (70.5%).
The median induction period was 3 days after immunization. Increased disproportionality for myopericarditis was found for NVX-CoV2373 (ROR 14.47, 95% confidence interval [CI] 11.22–18.67) and mRNA vaccines: BNT162b2 (ROR 17.15, 95% CI 16.88–17.42) and mRNA-1273 (ROR 6.92, 95% CI 6.77–7.08).
Higher values were found in males. The adenoviral vector-based vaccine Ad26.COV2.S showed slightly increased disproportionality (ROR 1.83, 95% CI 1.70–1.98), whereas no increased disproportionality was found for ChAdOx1.’
Bottom line, 13% recovered and it appears that NOVAVAX has similar myocarditis risk as Pfizer et al.
The second study of interest:

https://aacijournal.biomedcentral.com/articles/10.1186/s13223-022-00750-7?utm_source=substack&utm_medium=email
‘Study design

A case series of two cases of post vaccination myopericarditis following the NVX-CoV2373 after also developing myopericarditis with BNT162b2.
Conclusion

To our knowledge, we are the first to describe post vaccination myopericarditis following NVX-CoV2373 after also developing myopericarditis with BNT162b2. The similarities in presentation between the reactions of both platforms would suggest a similar pathogenesis, although the exact mechanism remains unknown. Further studies are necessary to identify these mechanisms, as well as to identify biomarkers that may identify vulnerable populations. On-going vigilance is necessary to identify those who may be at an increased risk of post-COVID vaccine myopericarditis.’

Alexander COVID News-Dr. Paul Elias Alexander’s Newsletter is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

Go to Dr Alexancer on Substack
Author: Dr. Paul Alexander